Elimusertib-d3 (BAY 1895344-d3) is the deuterium labeled Elimusertib (BAY 1895344). Elimusertib is a potent, orally active and selective ATR inhibitor and has anti-tumor activity.Appearance:SolidBiological Activity:Elimusertib-d3 (BAY 1895344-d3) is
Elimusertib-d3 (BAY 1895344-d3) is the deuterium labeled Elimusertib (BAY 1895344). Elimusertib is a potent, orally active and selective ATR inhibitor and has anti-tumor activity.Appearance:SolidBiological Activity:Elimusertib-d3 (BAY 1895344-d3) is
Elimusertib-d3 (BAY 1895344-d3) is the deuterium labeled Elimusertib (BAY 1895344). Elimusertib is a potent, orally active and selective ATR inhibitor and has anti-tumor activity.Appearance:SolidBiological Activity:Elimusertib-d3 (BAY 1895344-d3) is
Elimusertib-d3 (BAY 1895344-d3) is the deuterium labeled Elimusertib (BAY 1895344). Elimusertib is a potent, orally active and selective ATR inhibitor and has anti-tumor activity.Appearance:SolidBiological Activity:Elimusertib-d3 (BAY 1895344-d3) is
Telisotuzumab vedotin (anti-c-Met) is an antibody-drug conjugate (ADCs) targeting c-Met. Telisotuzumab vedotin (anti-c-Met) consists of Monomethyl Auristatin E (MMAE), Telisotuzumab antibody and a cleavable mc-val-cit-PABC type linker. Telisotuzumab
Telisotuzumab vedotin (anti-c-Met) is an antibody-drug conjugate (ADCs) targeting c-Met. Telisotuzumab vedotin (anti-c-Met) consists of Monomethyl Auristatin E (MMAE), Telisotuzumab antibody and a cleavable mc-val-cit-PABC type linker. Telisotuzumab
Telisotuzumab vedotin (anti-c-Met) is an antibody-drug conjugate (ADCs) targeting c-Met. Telisotuzumab vedotin (anti-c-Met) consists of Monomethyl Auristatin E (MMAE), Telisotuzumab antibody and a cleavable mc-val-cit-PABC type linker. Telisotuzumab
Telisotuzumab vedotin (anti-c-Met) is an antibody-drug conjugate (ADCs) targeting c-Met. Telisotuzumab vedotin (anti-c-Met) consists of Monomethyl Auristatin E (MMAE), Telisotuzumab antibody and a cleavable mc-val-cit-PABC type linker. Telisotuzumab
Telisotuzumab vedotin (anti-c-Met) is an antibody-drug conjugate (ADCs) targeting c-Met. Telisotuzumab vedotin (anti-c-Met) consists of Monomethyl Auristatin E (MMAE), Telisotuzumab antibody and a cleavable mc-val-cit-PABC type linker. Telisotuzumab
Telisotuzumab vedotin (anti-c-Met) is an antibody-drug conjugate (ADCs) targeting c-Met. Telisotuzumab vedotin (anti-c-Met) consists of Monomethyl Auristatin E (MMAE), Telisotuzumab antibody and a cleavable mc-val-cit-PABC type linker. Telisotuzumab
Telisotuzumab vedotin (anti-c-Met) is an antibody-drug conjugate (ADCs) targeting c-Met. Telisotuzumab vedotin (anti-c-Met) consists of Monomethyl Auristatin E (MMAE), Telisotuzumab antibody and a cleavable mc-val-cit-PABC type linker. Telisotuzumab
Telisotuzumab vedotin (anti-c-Met) is an antibody-drug conjugate (ADCs) targeting c-Met. Telisotuzumab vedotin (anti-c-Met) consists of Monomethyl Auristatin E (MMAE), Telisotuzumab antibody and a cleavable mc-val-cit-PABC type linker. Telisotuzumab